eamdacademy.org-6baj-1792753252-e540472020 1792753252 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2024 3 2 Wei Liu Zhang Min Qiang Zhao 2024 10.68159/e540472020 https://eamdacademy.org/pub/journal/3/article/e540472020 Mirza MU, Ikram N. Integrated computational approach for virtual hit identification against Ebola viral proteins VP35 and VP40. Int J Mol Sci. 2016;17(1748):1-31. Hayat M, Gao T, Cao Y, Rafiq M, Zhuo L, Li YZ. Identification of prospective Ebola virus VP35 and VP40 protein inhibitors from myxobacterial natural products. Biomolecules. 2024;14(6):660. 10.3390/biom14060660 Bandyopadhyay B, Verma N, Chouhan U. In sillico analysis of newly identified potential drug lead compound against VP40 for the treatment of Ebola virus infection. Int J Adv Biotechnol Res. 2016;7(4):1357-65. Broni E, Ashley C, Adams J, Manu H, Aikins E, Okom M, et al. Cheminformatics-based study identifies potential Ebola VP40 inhibitors. Int J Mol Sci. 2023;24(7):6298. 10.3390/ijms24076298 Basu A, Mills DM, Mitchell D, Ndungo E, Williams JD, Herbert AS, et al. Novel small molecule entry inhibitors of Ebola virus. JID. 2015;212(2):425-34. Cui Q, Cheng H, Xiong R, Zhang G, Du R, Anantpadma M, et al. Identification of diaryl-quinoline compounds as entry inhibitors of Ebola virus. Viruses. 2018;10(12):678. 10.3390/v10120678 Li H, Ying T, Yu F, Lu L, Jiang S. Development of therapeutics for treatment of Ebola virus infection. Microb Infect. 2015;17(2):109-17. Liu CH, Hu YT, Wong SH, Lin LT. Therapeutic strategies against Ebola virus infection. Viruses. 2022;14(3):579. 10.3390/v14030579 Veljkovic V, Loiseau PM, Figadere B, Glisic S, Veljkovic N, Perovic VR, et al. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Res 2015;4(34):1-13. World Health Organization. Ebola Situation Reports; Available from: http://www.who.int/csr/ disease/ebola/situation reports/en/ 2016. Setlur AS, Naik SY, Skariyachan S. Herbal lead as ideal bioactive compounds against probable drug targets of Ebola virus in comparison with known chemical analog: a computational drug discovery perspective. Interdiscip Sci Comput Life Sci. 2017;9(2):254-77. Mohamed EAR, Abdelwahab SF, Alqaisi AM, Nasr AMS, Hassan HA. Identification of promising anti-EBOV inhibitors: De novo drug design, molecular docking, and molecular dynamics studies. R Soc Open Sci. 2022;9(9):220369. 10.1098/rsos.220369 Raj U, Varadwaj PK. Flavonoids as multi-target inhibitors for proteins associated with Ebola virus: in silico discovery using virtual screening and molecular docking studies. Interdiscip Sci Comput Life Sci. 2016;8(2):132-41. Darko LKS, Broni E, Amuzu DSY, Wilson MD, Parry CS, Kwofie SK. Computational study on potential novel anti-ebola virus protein VP35 natural compounds. Biomedicines. 2021;9(12):1796. 10.3390/biomedicines9121796 Plesko S, Volk H, Luksic M, Podlipnik C. In Silico study of plant polyphenols’ interactions with VP24-ebola virus membrane-associated protein. Acta Chim. Slov. 2015;62(3):555-64. Balmith M, Soliman MES. Potential Ebola drug targets-filling the gap: a critical step forward towards the design and discovery of potential drugs. Biologia. 2017;72(1):1-13. Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, Latheef SK, et al. Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus. Front Immunol. 2018;9:1803. 10.3389/fimmu.2018.01803 Priya JV, Prabha AS, Rajesh SV, Aroulmoji V, Gnanendra TS. High throughput screening for identification of potent inhibitors targeting Ebola virus major matrix protein VP40. Int J Adv Sci Eng. 2015;1(4):10-6. Balmith M, Faya M, Soliman ME. Ebola virus: a gap in drug design and discovery-experimental and computational perspective. Chem Biol Drug Des. 2017;89(3):297-308. Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. Plos One. 2013;8(4):e60579. Stefanik M, Valdes JJ, Ezebuo FC, Haviernik J, Uzochukwu IC, Fojtikova M, et al. FDA-approved drugs efavirenz, tipranavir, and dasabuvir inhibit replication of multiple flaviviruses in Vero cells. Microorganisms. 2020;8(4):599. 10.3390/microorganisms8040599 Sepehri S, Gharagani S, Saghaie L, Aghasadeghi MR, Fassihi A. QSAR and docking studies of some 1,2,3,4- tetrahydropyrimidines: evaluation of gp41 as possible target for anti-HIV-1 activity. Med Chem Res. 2015;24(4):1707-24. Sepehri S, Soleymani S, Zabihollahi R, Aghasadeghi MR, Sadat M, Saghaie L, et al. Synthesis, biological evaluation, and molecular docking studies of novel 4-[4-arylpyridin-1(4H)-yl]benzoic acid derivatives as antiHIV-1 agents. Chem Biodivers. 2017;14(12):e1700295. Li F, Li X, Liu X, Zhang L, You L, Zhao J, et al. Docking and 3D-QSAR studies on the Ah receptor binding affinities of polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), and dibenzofurans (PCDFs). Environ Toxicol Pharmacol. 2011;32(3):478-85. Refsgaard HHF, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Chistensen MS. In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem. 2005;48(3):805-11. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kapple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615-23.